Academic Journal
Critical Review on the Effect and Mechanism of Realgar Nanoparticles on Lymphoma: State of the Art on In-Vitro Biomedical Studies
| Title: | Critical Review on the Effect and Mechanism of Realgar Nanoparticles on Lymphoma: State of the Art on In-Vitro Biomedical Studies |
|---|---|
| Authors: | Wenxia, Ran, Xiuqin, Chen, Joshua, Grant, Shubham, Sharma, Kahtan A, Mohammed, Abhinav, Kumar, Mohamed, Abbas |
| Source: | Recent Patents on Nanotechnology. 19:581-591 |
| Publisher Information: | Bentham Science Publishers Ltd., 2025. |
| Publication Year: | 2025 |
| Subject Terms: | Lymphoma, 0211 other engineering and technologies, Antineoplastic Agents, Apoptosis, 02 engineering and technology, Sulfides, Arsenicals, 3. Good health, Patents as Topic, 0202 electrical engineering, electronic engineering, information engineering, Humans, Nanoparticles, Animals, Cell Proliferation |
| Description: | Lymphoma is a malignant tumor caused by abnormal proliferation of lymphocytes in the lymphatic system. Conventional treatments for lymphoma often have limitations, and new therapeutic strategies need to be explored. Realgar is an ancient Chinese medicine that has been used for centuries to treat a variety of ailments due to its therapeutic potential for various diseases, including cancer. However, it is a time-consuming waste and has a low absorption rate in the gastrointestinal tract, so it has the disadvantages of oral dose, potential toxicity, and low bioavailability. Recently, the development of nanotechnology has promoted the nanization of realgar particles, which have better physicochemical properties and higher bioavailability. The antitumor activity of Realgar nanoparticles against lymphoma has been demonstrated in preclinical studies. Realgar nanoparticles exhibit cytotoxic effects by inducing apoptosis and inhibiting the growth and proliferation of lymphoma cells. Moreover, these nanoparticles exert immunomodulatory effects by enhancing the activity of immune cells and promoting the cytotoxicity of T lymphocytes against lymphoma cells. Additionally, realgar nanoparticles have been shown to inhibit tumor angiogenesis, thereby restricting the blood supply and nutrient availability to lymphoma cells as exhibited in this patent comprehensive review. Despite promising preclinical data, further research on the role and mechanism of realgar nanoparticles in the treatment of lymphoma remains to be studied. Moreover, the translation of these findings into clinical practice requires rigorous evaluation through well-designed clinical trials. Realgar nanoparticles hold great potential as a novel therapeutic approach for lymphoma, and their development may contribute to the advancement of precision medicine in the field of oncology. |
| Document Type: | Article |
| Language: | English |
| ISSN: | 1872-2105 |
| DOI: | 10.2174/0118722105284287240621053904 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/38982696 |
| Accession Number: | edsair.doi.dedup.....c8903e25bf1f4777b619357f1f30baca |
| Database: | OpenAIRE |
Be the first to leave a comment!